sulfamethoxazole (gantanol) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Sulfamethoxazole is a synthetic antibacterial drug,which is used in combination with trimethoprim (Bactrim, Septra) for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria. Sulfamethoxazole acts by inhibiting folic acid synthesis via enzyme called dihydropteroate synthase.   NCATS

Chemistry

  • SMILES: CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
  • InChIKey: JLKIGFTWXXRPMT-UHFFFAOYSA-N
  • Mol. Mass: 253.278
  • ALogP: 1.37
  • ChEMBL Molecule:
    sulfamethoxazole  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Combination drugs

( phenazopyridine (gantanol), sulfamethoxazole (gantanol) )
|
( sulfamethoxazole (gantanol), trimethoprim - other names: bactrim, bactrim ds, bactrim pediatric, cotrim, cotrim d.s, septra ds, septra grape, sulfamethoprim, sulfamethoprim-ds, sulfamethoxazole and trimethoprim double strength, sulfamethoxazole and trimethoprim single strength, sulfatrim, sulfatrim-ds, sulfatrim pediatric, sulfatrim-ss, trimeth/sulfa )

Alternative names

3-(p-aminophenylsulfonamido)-5-methylisoxazole | 3-sulfanilamido-5-methylisoxazole | 4-amino-n-(5-methyl-3-isoxazolyl)benzenesulfonamide | acetylsulfamethoxazole | cotrimaxazole | cotrimoxazole | co-trimoxazole | gantanol | gantanol-ds | gantanole | gantanol (tn) | ro-42130 | sinomin | smx | sulfamethalazole | sulfamethoxazol | sulfamethoxazole | sulfamethoxazole sodium | sulfisomezole | sulphamethoxazole | suphamethoxazole | urobak

Organizations (238)

Research & Development (204)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (35)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (99)

Approved Indications (7)


 

Bronchitis, Chronic (approved 1973)

Diarrhea (approved 1973)

Dysentery, Bacillary (approved 1973)

Infections

Otitis Media (approved 1973)

Pneumonia, Pneumocystis

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (96)


 

Abscess (Phase 3)

Acquired Immunodeficiency Syndrome (Phase 4)

Anemia (Phase 4)

Anti-Bacterial Agents (Phase 4)

Ascites (Phase 2)

Aspergillus (Phase 3)

Astrocytoma (Phase 1)

Bacterial Infections (Phase 3)

Bacteriuria (Phase 4)

Brain Neoplasms (Phase 1)

Candidemia (Phase 3)

Candidiasis, Invasive (Phase 3)

Child Development (Phase 4)

Congenital Hyperinsulinism (Phase 2)

Congenital Microtia (Early Phase 1)

Coronavirus Infections (Phase 2)

COVID-19 (Phase 2/Phase 3)

Cystitis (Phase 4)

Deficiency Diseases (Phase 2)

Dermatology (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Diarrhea (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Drug Resistance, Bacterial (Phase 4)

Enterobacteriaceae Infections (Phase 3)

Fever (Phase 3)

Fungemia (Phase 3)

General Surgery (Phase 4)

Glioblastoma (Phase 1)

Graft Rejection (Phase 4)

Healthy Volunteers (Phase 1)

HIV (Phase 4)

HIV Infections (Phase 4)

Hospitalization (Phase 4)

Idiopathic Pulmonary Fibrosis (Phase 3)

Infant, Newborn (Phase 4)

Infections ()

Kidney Calculi (Phase 4)

Kidney Diseases (Phase 1/Phase 2)

Kidney Transplantation (Phase 1/Phase 2)

Leukemia (Phase 1/Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1/Phase 2)

Liver Cirrhosis (Phase 2)

Lung Diseases (Phase 2/Phase 3)

Lupus Erythematosus, Systemic (Phase 4)

Lymphoma (Phase 2)

Lymphoproliferative Disorders (Phase 1/Phase 2)

Malaria (Phase 4)

Measles (Phase 3)

Melioidosis (Phase 4)

Meningitis (Phase 3)

Methicillin-Resistant Staphylococcus aureus (Phase 4)

Multiple Myeloma (Phase 3)

Muscle Hypotonia (Phase 2)

Mycoses (Phase 3)

Mycosis Fungoides (Phase 3)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Myeloproliferative Disorders (Phase 1/Phase 2)

Neoplasms (Phase 1/Phase 2)

Neutropenia (Phase 4)

Nutrition Disorders (Phase 3)

Obesity (Phase 4)

Opportunistic Infections (Phase 4)

Osteomyelitis (Phase 2)

Pancreatic Neoplasms (Phase 1)

Peritonitis (Phase 3)

Pharmacokinetics (Phase 4)

Phencyclidine (Phase 4)

Pituitary Neoplasms (Phase 4)

Pneumocystis (Phase 3)

Pneumocystis Infections (Phase 3)

Pneumonia (Phase 4)

Pneumonia, Pneumocystis ()

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Pregnancy Complications (Phase 3)

Primary Prevention (Phase 4)

Prostatic Neoplasms (Phase 4)

Prosthesis-Related Infections (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Pyelonephritis (Phase 4)

Respiratory Tract Infections (Phase 2)

Sepsis (Phase 3)

Sexually Transmitted Diseases (Phase 2)

Skin Diseases, Infectious (Phase 4)

Staphylococcal Infections (Phase 3)

Staphylococcus aureus (Phase 2)

Toxoplasmosis, Ocular (Phase 3)

Tuberculosis (Phase 4)

Urinary Bladder Neoplasms (Phase 4)

Urinary Bladder, Neurogenic (Phase 4)

Urinary Tract Infections ()

Vesico-Ureteral Reflux (Phase 3)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 134
  • # of Trial Organizations: 204

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue